It is suggested that a decrease in TCL1A levels may contribute to chemo-induced cardiomyopathy by increasing apoptotic sensitivity, decreasing cardiac MDR1, and increasing doxorubicin and intracellular free radical concentrations [23]. This evidence concerns the gene TCL1A and cardiomyopathy.